Clinical predictors of response to adjunctive brivaracetam: Insights from real-world data
Epilepsia
.
2022 Jan;63(1):252-253.
doi: 10.1111/epi.17123.
Epub 2021 Nov 14.
Authors
Simona Lattanzi
1
,
Valentina Chiesa
2
,
Edoardo Ferlazzo
3
,
Angela La Neve
4
,
Pietro Pignatta
5
,
Carlo Di Bonaventura
6
;
BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST) Group
Affiliations
1
Department of Experimental and Clinical Medicine, Neurological Clinic, Marche Polytechnic University, Ancona, Italy.
2
Child Neuropsychiatry Unit, Epilepsy Center, AAST Santi Paolo Carlo, Milan, Italy.
3
Department of Medical and Surgical Sciences, Magna Graecia University of Catanzaro, Catanzaro, Italy.
4
Department of Basic Medical Sciences, Neurosciences, and Sense Organs, University Hospital of Bari "A. Moro,", Bari, Italy.
5
Neurology and Epilepsy Unit, Humanitas Gradenigo Hospital, Turin, Italy.
6
Department of Human Neurosciences, Umberto I Polyclinic, Sapienza University of Rome, Rome, Italy.
PMID:
34778953
DOI:
10.1111/epi.17123
No abstract available
Keywords:
antiseizure medications; brivaracetam; epilepsy; focal seizures.
Publication types
Letter
Comment
MeSH terms
Anticonvulsants* / therapeutic use
Pyrrolidinones* / therapeutic use
Substances
Anticonvulsants
Pyrrolidinones
brivaracetam